DelveInsight’s, “Ocular Hypertension Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Ocular Hypertension pipeline landscape. It covers the Ocular Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ocular Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight
Key Takeaways from the Ocular Hypertension Pipeline Report
Learn how leading Ocular Hypertension Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Ocular Hypertension Clinical Trials Assessment
Ocular Hypertension Emerging Drugs Profile
Sepetaprost (STN1012600) is a dual agonist of the FP and EP3 receptors, using as its active ingredient sepetaprost, a compound originally developed and manufactured by Ono Pharmaceutical Co., Ltd. STN1012600 is a prostaglandin derivative for the treatment of glaucoma and ocular hypertension that contains 0.002% sepetaprost and has a novel mechanism of action for lowering intraocular pressure. It works by selectively binding to both the FP and EP3 receptors in the eye, promoting increased aqueous humor outflow through both the uveoscleral and trabecular pathways. This dual action helps to lower intraocular pressure more effectively. By targeting these specific receptors, STN1012600 may offer improved efficacy with fewer side effects compared to traditional treatments. Currently, the drug is in Preregistration stage of its development for the treatment of Ocular Hypertension.
NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. NCX 470 is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small, naturally occurring signaling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase (sGC). NO brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action to that of PGAs. Currently, the drug is in Phase III stage of its development for the treatment of Ocular Hypertension.
QLS-111 is a novel formulation developed by Qlaris Bio that utilizes an ATP-sensitive potassium (KATP) channel modulator platform to effectively lower intraocular pressure (IOP). Its mechanism of action involves relaxing the vascular and vascular-like tissues located distal to the trabecular meshwork, which leads to a reduction in distal outflow resistance. By enhancing the outflow of aqueous humor, QLS-111 simultaneously lowers episcleral venous pressure (EVP), a critical factor that contributes significantly to IOP. This dual action not only helps to alleviate the pressure within the eye but also addresses an often-overlooked component of IOP regulation, potentially offering a more comprehensive approach to managing conditions such as glaucoma and ocular hypertension. Currently, the drug is in Phase II stage of its development for the treatment of Ocular Hypertension.
H-1337 is an advanced multi-kinase inhibitor under development for the treatment of glaucoma and ocular hypertension, designed to lower intraocular pressure (IOP) through a novel mechanism of action. This compound primarily inhibits leucine-rich repeat kinase 2 (LRRK2), a serine/threonine kinase that plays a vital role in regulating the cytoskeletal dynamics of trabecular meshwork cells. By inhibiting LRRK2, H-1337 promotes the depolymerization of microtubules within these cells, leading to structural changes that enhance aqueous humor drainage through the trabecular meshwork and Schlemm’s canal. Additionally, H-1337 also exhibits secondary activity as a Rho-associated protein kinase (ROCK) inhibitor, further contributing to its efficacy in reducing IOP. This dual-action approach not only addresses the primary challenge of elevated IOP in glaucoma patients but also positions H-1337 as a promising candidate for improving overall ocular health. Currently, the drug is in Phase II stage of its development for the treatment of Ocular Hypertension.
RTC-1119 is an innovative intracameral implant developed by Ripple Therapeutics for the treatment of primary open-angle glaucoma. This formulation utilizes a unique prodrug of latanoprost acid, designed to provide sustained release of the active drug through a surface erosion mechanism. The implant is engineered to dissolve gradually, allowing for controlled and predictable drug delivery over an extended period, typically exceeding six months. By enhancing the outflow of aqueous humor and reducing intraocular pressure (IOP), RTC-1119 aims to improve patient compliance and therapeutic outcomes in managing glaucoma. The absence of polymers in its composition further minimizes potential inflammatory responses, making RTC-1119 a promising candidate in the evolving landscape of glaucoma therapies. Currently, the drug is in Preclinical stage of its development for the treatment of Ocular Hypertension.
The Ocular Hypertension Pipeline report provides insights into
From early-stage research to late-phase Ocular Hypertension Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs @ Ocular Hypertension Treatment Drugs
Ocular Hypertension Companies
Santen Pharmaceutical, Nicox Ophthalmics, Inc., Allysta Pharmaceuticals, Qlaris Bio, Inc., Ripple Therapeutics, Laboratoires Thea, Ocular Therapeutix, Inc., Otsuka Beijing Research Institute, Alcon Research, AbbVie, Glaukos Corporation, MediPrint Ophthalmics, Ocuphire Pharma and others.
Ocular Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Ocular Hypertension Products have been categorized under various Molecule types such as
Stay updated with the latest Ocular Hypertension Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Ocular Hypertension Market Drivers and Barriers, and Future Perspectives
Scope of the Ocular Hypertension Pipeline Report
Find answers in our latest Ocular Hypertension Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs @ Ocular Hypertension Emerging Drugs and Companies
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/report-store/ocular-hypertension-pipeline-insight
